Ethiopia

Population 2018: 109 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>165 (116–223)</td>
<td>151 (107–204)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>7.6 (5.3–10)</td>
<td>7 (4.9–9.4)</td>
</tr>
<tr>
<td>MDR-RR-TB incidenceºº</td>
<td>1.6 (1–2.2)</td>
<td>1.4 (0.96–2)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>24 (15–36)</td>
<td>22 (14–33)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>2.2 (1.5–3)</td>
<td>2 (1.4–2.8)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/R-R-TB, 2018
New cases: 0.71% (0.62–0.8)  
Previously treated cases: 16% (14–17)

TB case notifications, 2018
Total new and relapse: 113,613
- % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status: 92%
  - % pulmonary: 69%
  - % bacteriologically confirmedººº: 62%
  - % children aged 0–14 years: 10%
  - % women: 40%
  - % men: 50%
Total cases notified: 114,233

Universal health coverage and social protection
TB treatment coverage (notified/estimated incidence), 2018: 69% (51–98)
TB patients facing catastrophic total costs: 17% (9–25)

TB/HIV care in new and relapse TB patients, 2018
Patients with known HIV status who are HIV-positive: 4,816 (5%)
  - on antiretroviral therapy: 4,393 (91%)

Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance ºº
  - New cases: 80%
  - Previously treated cases: 100%

Laboratory-confirmed cases*
  MDR/R-R-TB: 741, XDR-TB: 3

Patients started on treatment*
  MDR/R-R-TB: 747, XDR-TB: 3

MDR/R-R-TB cases tested for resistance to second-line drugs: 360

Treatment success rate and cohort size
New cases registered in 2017: 96% (113,690)
Previously treated cases registered in 2017
MDR-R-R-TB cases started on second-line treatment in 2016: 72% (703)
XDR-TB cases started on second-line treatment in 2016

TB preventive treatment, 2018
% of HIV-positive people (newly enrolled in care) on preventive treatment: 49%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 22% (20–24)

TB financing, 2019
National TB budget (US$ millions): 94
Funding source: 11% domestic, 29% international, 60% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR burden are produced by WHO in consultation with countries.
Generated: 2020-03-19  
Data: www.who.int/tb/data